CytoMed Common Stock vs Inventory Analysis

GDTC Stock

2.29 0.67 22.64%

CytoMed Therapeutics financial indicator trend analysis is way more than just evaluating CytoMed Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytoMed Therapeutics is a good investment. Please check the relationship between CytoMed Therapeutics Common Stock and its Inventory accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Common Stock vs Inventory

Common Stock vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytoMed Therapeutics Common Stock account and Inventory. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between CytoMed Therapeutics' Common Stock and Inventory is -0.62. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Inventory in the same time period over historical financial statements of CytoMed Therapeutics Limited, assuming nothing else is changed. The correlation between historical values of CytoMed Therapeutics' Common Stock and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of CytoMed Therapeutics Limited are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Common Stock i.e., CytoMed Therapeutics' Common Stock and Inventory go up and down completely randomly.

Correlation Coefficient

-0.62

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Common Stock

Inventory

Most indicators from CytoMed Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytoMed Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

The current year's Issuance Of Capital Stock is expected to grow to about 13.7 M, whereas Tax Provision is forecasted to decline to 630.58.

	2022	2023	2024	2025 (projected)
Other Operating Expenses	1.4M	3.2M	3.7M	3.9M
Depreciation And Amortization	291.8K	77.5K	69.7K	66.2K

Other Operating Expenses Depreciation And Amortization

CytoMed Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		-0.23	0.78	0.04	0.98	-0.67	-0.85	-0.96	-0.91	0.66	1.0	0.23	0.99	1.0	0.99	-0.38	0.88	-0.49	-0.73	-0.66	0.74	0.18	1.0	-0.14	-0.81	1.0
Short Long Term Debt Total	-0.23		-0.28	0.96	-0.42	-0.19	-0.28	0.43	-0.12	0.13	-0.22	-0.82	-0.18	-0.23	-0.21	-0.69	0.01	-0.73	-0.49	0.86	0.45	0.88	-0.19	1.0	-0.28	-0.19
Other Current Liab	0.78	-0.28		-0.04	0.77	-0.71	-0.65	-0.82	-0.77	0.36	0.79	0.35	0.81	0.79	0.82	0.02	0.89	-0.22	-0.51	-0.64	0.61	-0.07	0.78	-0.21	-0.72	0.8
Total Current Liabilities	0.04	0.96	-0.04		-0.16	-0.4	-0.52	0.17	-0.39	0.29	0.05	-0.78	0.09	0.04	0.06	-0.79	0.26	-0.87	-0.71	0.69	0.67	0.95	0.08	0.98	-0.52	0.08
Total Stockholder Equity	0.98	-0.42	0.77	-0.16		-0.57	-0.73	-0.98	-0.82	0.61	0.98	0.39	0.95	0.98	0.97	-0.21	0.81	-0.3	-0.58	-0.79	0.59	-0.02	0.97	-0.34	-0.7	0.97
Net Tangible Assets	-0.67	-0.19	-0.71	-0.4	-0.57		0.8	0.58	0.77	-0.18	-0.68	0.27	-0.75	-0.68	-0.74	0.5	-0.69	0.57	0.73	0.28	-0.72	-0.48	-0.69	-0.25	0.7	-0.71
Property Plant And Equipment Net	-0.85	-0.28	-0.65	-0.52	-0.73	0.8		0.73	0.93	-0.72	-0.86	0.27	-0.89	-0.85	-0.85	0.7	-0.86	0.83	0.95	0.24	-0.96	-0.59	-0.87	-0.36	0.89	-0.85
Net Debt	-0.96	0.43	-0.82	0.17	-0.98	0.58	0.73		0.83	-0.6	-0.96	-0.36	-0.96	-0.97	-0.96	0.14	-0.84	0.28	0.56	0.8	-0.6	0.06	-0.96	0.35	0.71	-0.95
Retained Earnings	-0.91	-0.12	-0.77	-0.39	-0.82	0.77	0.93	0.83		-0.66	-0.91	0.05	-0.93	-0.91	-0.92	0.52	-0.93	0.72	0.9	0.36	-0.91	-0.45	-0.92	-0.21	0.97	-0.93
Accounts Payable	0.66	0.13	0.36	0.29	0.61	-0.18	-0.72	-0.6	-0.66		0.67	-0.04	0.64	0.66	0.59	-0.46	0.69	-0.64	-0.69	-0.2	0.74	0.3	0.67	0.2	-0.67	0.63
Cash	1.0	-0.22	0.79	0.05	0.98	-0.68	-0.86	-0.96	-0.91	0.67		0.21	0.99	1.0	0.99	-0.38	0.88	-0.49	-0.74	-0.66	0.74	0.18	1.0	-0.14	-0.81	1.0
Non Current Assets Total	0.23	-0.82	0.35	-0.78	0.39	0.27	0.27	-0.36	0.05	-0.04	0.21		0.13	0.22	0.21	0.64	0.14	0.61	0.38	-0.64	-0.33	-0.75	0.19	-0.82	0.08	0.21
Non Currrent Assets Other	0.99	-0.18	0.81	0.09	0.95	-0.75	-0.89	-0.96	-0.93	0.64	0.99	0.13		0.99	0.99	-0.39	0.89	-0.52	-0.76	-0.64	0.77	0.21	0.99	-0.09	-0.82	0.98
Cash And Short Term Investments	1.0	-0.23	0.79	0.04	0.98	-0.68	-0.85	-0.97	-0.91	0.66	1.0	0.22	0.99		0.99	-0.38	0.88	-0.49	-0.73	-0.66	0.74	0.18	1.0	-0.14	-0.81	1.0
Net Receivables	0.99	-0.21	0.82	0.06	0.97	-0.74	-0.85	-0.96	-0.92	0.59	0.99	0.21	0.99	0.99		-0.37	0.89	-0.48	-0.74	-0.65	0.74	0.2	0.99	-0.13	-0.82	1.0
Good Will	-0.38	-0.69	0.02	-0.79	-0.21	0.5	0.7	0.14	0.52	-0.46	-0.38	0.64	-0.39	-0.38	-0.37		-0.32	0.91	0.81	-0.34	-0.7	-0.93	-0.41	-0.73	0.54	-0.4
Common Stock Shares Outstanding	0.88	0.01	0.89	0.26	0.81	-0.69	-0.86	-0.84	-0.93	0.69	0.88	0.14	0.89	0.88	0.89	-0.32		-0.58	-0.8	-0.43	0.87	0.25	0.89	0.09	-0.93	0.89
Short Term Investments	-0.49	-0.73	-0.22	-0.87	-0.3	0.57	0.83	0.28	0.72	-0.64	-0.49	0.61	-0.52	-0.49	-0.48	0.91	-0.58		0.94	-0.31	-0.9	-0.91	-0.52	-0.78	0.77	-0.51
Non Current Liabilities Total	-0.73	-0.49	-0.51	-0.71	-0.58	0.73	0.95	0.56	0.9	-0.69	-0.74	0.38	-0.76	-0.73	-0.74	0.81	-0.8	0.94		-0.01	-0.98	-0.77	-0.76	-0.57	0.92	-0.76
Inventory	-0.66	0.86	-0.64	0.69	-0.79	0.28	0.24	0.8	0.36	-0.2	-0.66	-0.64	-0.64	-0.66	-0.65	-0.34	-0.43	-0.31	-0.01		-0.04	0.58	-0.63	0.81	0.17	-0.62
Other Current Assets	0.74	0.45	0.61	0.67	0.59	-0.72	-0.96	-0.6	-0.91	0.74	0.74	-0.33	0.77	0.74	0.74	-0.7	0.87	-0.9	-0.98	-0.04		0.67	0.76	0.53	-0.94	0.76
Total Liab	0.18	0.88	-0.07	0.95	-0.02	-0.48	-0.59	0.06	-0.45	0.3	0.18	-0.75	0.21	0.18	0.2	-0.93	0.25	-0.91	-0.77	0.58	0.67		0.21	0.91	-0.53	0.22
Total Current Assets	1.0	-0.19	0.78	0.08	0.97	-0.69	-0.87	-0.96	-0.92	0.67	1.0	0.19	0.99	1.0	0.99	-0.41	0.89	-0.52	-0.76	-0.63	0.76	0.21		-0.11	-0.83	1.0
Short Term Debt	-0.14	1.0	-0.21	0.98	-0.34	-0.25	-0.36	0.35	-0.21	0.2	-0.14	-0.82	-0.09	-0.14	-0.13	-0.73	0.09	-0.78	-0.57	0.81	0.53	0.91	-0.11		-0.36	-0.1
Intangible Assets	-0.81	-0.28	-0.72	-0.52	-0.7	0.7	0.89	0.71	0.97	-0.67	-0.81	0.08	-0.82	-0.81	-0.82	0.54	-0.93	0.77	0.92	0.17	-0.94	-0.53	-0.83	-0.36		-0.84
Common Stock	1.0	-0.19	0.8	0.08	0.97	-0.71	-0.85	-0.95	-0.93	0.63	1.0	0.21	0.98	1.0	1.0	-0.4	0.89	-0.51	-0.76	-0.62	0.76	0.22	1.0	-0.1	-0.84

Click cells to compare fundamentals

CytoMed Therapeutics Account Relationship Matchups

CytoMed Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	2.9M	4.5M	3.9M	12.4M	14.2M	14.9M
Short Long Term Debt Total	2.3M	2.4M	3.1M	448.0K	515.2K	489.5K
Other Current Liab	326.7K	176.1K	400.3K	643.7K	740.2K	411.8K
Total Current Liabilities	2.1M	2.2M	3.1M	716.9K	824.5K	783.3K
Total Stockholder Equity	359.6K	1.9M	436.0K	8.5M	9.8M	10.3M
Property Plant And Equipment Net	1.7M	1.8M	1.8M	1.6M	1.4M	1.5M
Net Debt	1.6M	551.6K	2.0M	(8.5M)	(7.7M)	(7.3M)
Retained Earnings	(2.3M)	(3.7M)	(6.1M)	(9.3M)	(8.4M)	(8.0M)
Accounts Payable	14.3K	34.2K	10.9K	24.6K	28.3K	21.2K
Cash	668.8K	1.9M	1.2M	9.0M	10.3M	10.9M
Non Current Assets Total	1.8M	2.1M	2.0M	2.3M	2.6M	2.3M
Non Currrent Assets Other	(1.8M)	(2.1M)	(2.0M)	546.7K	628.7K	660.1K
Cash And Short Term Investments	668.8K	1.9M	1.2M	9.0M	10.3M	10.9M
Net Receivables	9.1K	3.9K	42.8K	204.7K	235.5K	247.2K
Common Stock Shares Outstanding	5.9M	6.9M	7.9M	10.6M	12.2M	8.1M
Short Term Investments	32.9K	11.3K	11.6K	47.8K	43.0K	30.0K
Liabilities And Stockholders Equity	2.9M	4.5M	3.9M	12.4M	14.2M	14.9M
Non Current Liabilities Total	464.0K	410.0K	353.3K	407.8K	367.0K	361.6K
Inventory	181.6K	319.1K	428.0K	(204.7K)	(184.3K)	(175.1K)
Other Current Assets	571.7K	763.7K	856.6K	896.8K	1.0M	688.6K
Other Stockholder Equity	(6.3K)	1.1M	(94.7K)	(32.6K)	(29.3K)	(27.9K)
Total Liab	2.5M	2.6M	3.4M	1.1M	1.3M	2.3M
Total Current Assets	1.1M	2.4M	1.9M	10.1M	11.6M	12.2M
Accumulated Other Comprehensive Income	(6.3K)	(22.9K)	(94.7K)	(108.7K)	(97.8K)	(93.0K)
Short Term Debt	1.8M	2.0M	2.8M	40.3K	46.3K	44.0K
Intangible Assets	33.9K	23.4K	13.7K	12.1K	10.9K	19.0K
Common Stock	2.6M	4.8M	6.6M	18.0M	20.7M	21.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:

How To Invest In CytoMed

Details

Is CytoMed Stock a good investment?

Details

What is CytoMed Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.22)

Revenue Per Share

0.039

Quarterly Revenue Growth

(0.21)

Return On Assets

(0.17)

Return On Equity

(0.26)

The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytoMed Common Stock vs Inventory Analysis

Common Stock vs Inventory

Common Stock vs Inventory Correlation Analysis

Correlation Coefficient

Common Stock

Inventory

CytoMed Therapeutics fundamental ratios Correlations

CytoMed Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytoMed Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Total Assets
Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash

Other Current Assets	- 0.98	Non Current Liabilities Total
Net Debt	- 0.98	Total Stockholder Equity
Cash And Short Term Investments	- 0.97	Net Debt
Total Current Assets	- 0.96	Net Debt
Net Receivables	- 0.96	Net Debt
Non Currrent Assets Other	- 0.96	Net Debt